Smith & Nephew plc (SNN) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Smith & Nephew plc (SNN) Healthcare & Pipeline Overview

Smith & Nephew plc (SNN) is a global medical device company focused on orthopedic reconstruction, sports medicine, and advanced wound management. With a diverse portfolio of innovative products and a presence in over 100 countries, SNN addresses critical needs in the healthcare sector, competing with major players in the medical device industry.

What Is the Investment Thesis for SNN?

The company's focus on high-growth segments within the medical device industry, such as sports medicine and advanced wound management, positions it for sustained revenue growth. With a market capitalization of $11.6B and a profit margin of 10.1%, SNN demonstrates financial stability. A dividend yield of 2.65% offers investors an income stream. Upcoming product launches and expansion into emerging markets could serve as catalysts for further growth. Potential risks include increasing competition and regulatory changes in the healthcare industry. The company's P/E ratio of 18.30 suggests a reasonable valuation relative to its earnings.

Based on FMP financials and quantitative analysis

SNN Key Highlights

Market capitalization of $11.6B indicates a substantial and established company within the medical device industry.

• Profit margin of 10.1% demonstrates efficient operations and profitability in a competitive market.
• Gross margin of 68.0% reflects strong pricing power and efficient cost management in product manufacturing.
• Dividend yield of 2.65% provides an attractive income stream for investors, highlighting the company's commitment to shareholder returns.
• Beta of 0.74 suggests lower volatility compared to the overall market, indicating a relatively stable investment.

Who Are SNN's Competitors?

SNN is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are SNN's Key Strengths?

Diversified product portfolio across orthopedic reconstruction, sports medicine, and advanced wound management.

• Global presence with operations in over 100 countries.
• Strong brand reputation and established relationships with healthcare providers.
• Commitment to research and development, driving innovation in medical devices.

What Are SNN's Weaknesses?

Exposure to currency fluctuations due to international operations.

• Dependence on regulatory approvals for new products.
• Intense competition from larger medical device companies.
• Potential for product liability claims.

What Could Drive SNN Stock Higher?

SNN catalyst: New product launches in the orthopedic reconstruction and sports medicine segments are expected to drive revenue growth in the next 12-18 months.

• Expansion into emerging markets, particularly in Asia-Pacific, is expected to contribute to long-term growth.
• Continued investment in research and development is expected to lead to innovative medical devices and technologies.
• Potential acquisitions of smaller, innovative companies could expand the company's product portfolio and geographic reach.

What Are the Key Risks for SNN?

Increasing competition from established and emerging medical device companies could put pressure on pricing and market share.

• Changes in healthcare regulations and reimbursement policies could negatively impact the company's profitability.
• Economic downturns could reduce healthcare spending and demand for medical devices.
• Product liability claims could result in significant financial losses and reputational damage.
• Currency fluctuations could negatively impact the company's financial results.

What Are the Growth Opportunities for SNN?

• Expansion in Emerging Markets: Smith & Nephew has a significant opportunity to expand its presence in emerging markets, such as China and India, where healthcare spending is rapidly increasing. The rising middle class and growing awareness of advanced medical treatments are driving demand for orthopedic reconstruction, sports medicine, and advanced wound management products. The emerging markets medical device market is projected to reach $200 billion by 2030, offering substantial growth potential for SNN.
• New Product Innovation: Smith & Nephew's commitment to research and development provides a strong foundation for new product innovation. The company can leverage its expertise in biomaterials, robotics, and digital technologies to develop next-generation medical devices that improve patient outcomes and reduce healthcare costs. The market for innovative medical devices is estimated at $150 billion annually, with significant opportunities for companies that can deliver breakthrough technologies.
• Strategic Acquisitions: Smith & Nephew can pursue strategic acquisitions to expand its product portfolio, geographic reach, and technological capabilities. Acquisitions of smaller, innovative companies can provide access to new markets and technologies, while larger acquisitions can enhance economies of scale and market share. The medical device industry is highly fragmented, with numerous potential acquisition targets.
• Digital Health Integration: Smith & Nephew can integrate digital health technologies into its products and services to enhance patient engagement, improve clinical outcomes, and reduce healthcare costs. The company can develop mobile apps, wearable sensors, and remote monitoring systems that provide real-time data to patients and healthcare providers.
• Advanced Wound Management: The global advanced wound care market is expected to reach $22 billion by 2027, driven by the increasing prevalence of chronic diseases such as diabetes and obesity. Smith & Nephew can capitalize on this trend by developing and marketing innovative wound care products that promote faster healing and reduce the risk of infection. The company's expertise in bioactive technologies and negative pressure wound therapy positions it well to capture a significant share of this growing market.

What Are SNN's Competitive Advantages?

• Strong brand reputation and established relationships with healthcare providers.
• Extensive portfolio of innovative medical devices and technologies.
• Global distribution network and presence in key markets.
• Significant investment in research and development.
• Regulatory expertise and compliance capabilities.

What Does SNN Do?

Founded in 1856 in Hull, England, Smith & Nephew began as a small pharmacy that evolved into a manufacturer of surgical dressings. Over the decades, the company expanded its product line and geographic reach through strategic acquisitions and organic growth. Today, Smith & Nephew plc is a global leader in medical technology, specializing in orthopedic reconstruction, sports medicine, and advanced wound management. The company's orthopedic reconstruction division offers a comprehensive range of hip and knee implants designed to improve patient outcomes and reduce recovery times. The sports medicine division provides innovative solutions for the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder. Smith & Nephew's advanced wound management division develops and markets a wide range of products for the treatment and prevention of acute and chronic wounds, including leg ulcers, diabetic foot ulcers, and pressure ulcers. Headquartered in Watford, United Kingdom, Smith & Nephew serves healthcare providers in over 100 countries, with a strong presence in North America, Europe, and Asia-Pacific. The company's commitment to innovation and customer satisfaction has enabled it to maintain a leading position in the competitive medical device industry.

What Products and Services Does SNN Offer?

• Develops and manufactures orthopedic reconstruction implants for hip and knee replacement procedures.
• Offers sports medicine joint repair products for minimally invasive surgery of the joints.
• Provides trauma and extremities products for the stabilization of severe fractures.
• Supplies arthroscopic enabling technologies, including fluid management equipment and high-definition cameras.
• Offers advanced wound care products for the treatment and prevention of acute and chronic wounds.
• Provides advanced wound bioactives, including biologics and other bioactive technologies for debridement and dermal repair/regeneration.
• Develops regenerative medicine products including skin, bone graft, and articular cartilage substitutes.

How Does SNN Make Money?

• Smith & Nephew generates revenue through the sale of medical devices and related products to healthcare providers.
• The company operates through a direct sales force and a network of distributors.
• Smith & Nephew invests heavily in research and development to create innovative products and maintain a competitive edge.
• The company focuses on building strong relationships with surgeons and other healthcare professionals to drive product adoption.

What Industry Does SNN Operate In?

Smith & Nephew operates in the global medical device industry, which is characterized by continuous innovation and increasing demand driven by an aging population and rising healthcare expenditures. The industry is highly competitive, with major players such as Johnson & Johnson, Stryker, and Zimmer Biomet. Smith & Nephew differentiates itself through its focus on specific segments, including sports medicine and advanced wound management. The global medical device market is projected to reach $600 billion by 2026, with a compound annual growth rate (CAGR) of approximately 5-7%.

Who Are SNN's Key Customers?

• Hospitals and surgical centers
• Orthopedic surgeons
• Sports medicine physicians
• Wound care specialists
• Healthcare providers in over 100 countries

Smith & Nephew plc has beaten Wall Street's EPS estimate in 4 of its last 8 reported quarters — more hits than misses. Reported results have landed about 1.8% below estimates on average.

Quarterly Financial Performance: Smith & Nephew plc

Revenue for Smith & Nephew plc came in at $3.10B during Q2 FY2026, a 3.3% contraction versus the preceding quarter. The company recorded net income of $303.0M, with diluted EPS of $0.70. Quarter-over-quarter revenue has been mixed, typical for a large-cap company operating in Healthcare. Across the four most recent quarters, SNN averaged $0.65 in diluted EPS.

SNN Valuation & Market Position

With a $11.6B market cap, Smith & Nephew plc sits in the large-cap segment of the market. Analyst price targets span from $30.00 to $31.85, with a consensus of $30.93. At the current price of $27.62, that implies approximately 12% upside potential. Relative to its peer group, SNN's quantitative score of 85/100 is roughly in line with the peer average of 79/100.

Return on equity for Smith & Nephew plc stands at 12.2%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 5.8%, showing how much profit it generates from its asset base. SNN trades at a trailing price-to-earnings ratio of 18.30, below the Healthcare sector average of ~21.50x. Its free cash flow yield is 7.3%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.14 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 5.5%, the inverse of the P/E and a quick read on earnings relative to price.

Smith & Nephew plc's Piotroski F-Score is 8/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 3.82 places it in the safe zone, indicating low near-term bankruptcy risk.

Company Profile

Smith & Nephew plc operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Watford, GB. The company is led by CEO Deepak S. Nath. SNN has traded publicly since 1999.

SNN Financials

SNN Latest News

SNN Analyst Consensus

SNN MoonshotScore

What Investors Ask About Smith & Nephew plc (SNN) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources